The American Society of Clinical Oncology (ASCO) is a platform for cancer experts to share views on latest advancement and new approaches in cancer research. In the 55th session of […]readmore
Tags : Seattle Genetics
Shots: The P-II EV-201 study involves assessing of Enfortumab Vedotin in patients with locally advanced or metastatic urothelial cancer who have been previously treated with a PD-1/L1 inhibitor including those […]readmore
Shots: The FDA’s BT designation is based on P-III ECHELON-2 study results assessing Adcetris + CHP vs CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in 450 patients with CD30+ T-cell lymphoma across […]readmore
Shots: The Multiple Studies P-III ECHELON-1 (Adcetris + CT vs CT), P-I/II & P-II (Adcetris + Opdivo(nivolumab)) and P-III AETHERA (Adcetris) is evaluated in patients with stage III or IV […]readmore